A prospective active post marketing surveillance study to assess safety and effectiveness of Remogliflozin and Remogliflozin-Metformin Fixed Dose Combination in management of Type 2 Diabetes Mellitus patients in Real world setting - REMOLUTION

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metformin/remogliflozin-etabonate (Primary) ; Remogliflozin etabonate (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Acronyms REMOLUTION
Sponsors Glenmark Pharmaceuticals Ltd

Most Recent Events

19 May 2020 Status changed from not yet recruiting to recruiting.
29 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight